does anyone have any thoughts as to what qcor's strategy will be with the newly acquired rights to Synacthen? Pricing, marketing, positioning with Acthar, etc?
It seems like it may offer a glide path into Europe, perhaps globally, to market Acthar?
Sentiment: Strong Buy
This is something I would like to know too. CC should provide a great deal of info on this subject hopefully.
As per acquisition date, Synacthen sales should immediately accrue to QCOR revenue.